DISC-0974 for IBD and Anemia
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 2, multicenter, randomized, double-blind placebo-controlled study of DISC-0974 to evaluate safety, tolerability, and efficacy in participants with IBD and anemia of inflammation.
Who Is on the Research Team?
Will Savage, MD, PhD
Principal Investigator
Disc Medicine
Are You a Good Fit for This Trial?
Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- DISC-0974
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
DISC-0974 60 mg (n = 14) administered subcutaneously (SC) every 28 days for 3 doses
Placebo (n = 7) administered SC every 28 days for 3 doses
Find a Clinic Near You
Who Is Running the Clinical Trial?
Disc Medicine, Inc
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.